Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business UpdatePRNewsWire • 08/01/22
Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing CholangitisPRNewsWire • 06/27/22
Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022PRNewsWire • 06/02/22
Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment ConferencePRNewsWire • 05/18/22
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 05/12/22
Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business UpdatePRNewsWire • 05/04/22
Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease SummitPRNewsWire • 03/23/22
Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic SclerosisPRNewsWire • 03/14/22
Chemomab Therapeutics Ltd (CMMB) CEO Dale Pfost on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/09/22
Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate UpdatePRNewsWire • 03/09/22
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business UpdatePRNewsWire • 03/02/22
Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development OperationsPRNewsWire • 01/04/22
Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare ConferencePRNewsWire • 12/20/21
Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the BoardPRNewsWire • 12/16/21
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical OfficerPRNewsWire • 12/03/21
Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate UpdatePRNewsWire • 11/12/21
Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating OfficerPRNewsWire • 11/08/21
Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic SclerosisPRNewsWire • 09/27/21